ADAR and cholangiocarcinoma: Finally, the epigenomic analysis of DNA methylation levels at ADAR1 promoter in the dataset from Roessler’s cohort (GSE201241) [31] and TCGA-CHOL-iCCA cohort showed no significant difference between the cholangiocarcinoma tissues and non-tumor liver tissues or non-tumor bile duct tissues (Supplementary Fig. 2D and E).